SCHEMBL3003591

SCHEMBL3003591

CCOC(=O)c1c(C)nc2[nH]ncc2c1-c1ccccc1-c1cccc(C(C)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 3/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 3/20 0.42
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADORA3 P0DMS8 2/20 0.40
FYN P06241 1/20 0.39
BTK Q06187 1/20 0.39
ITK Q08881 1/20 0.39
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010306 0.82 LMNA (0.48) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL3006574 0.82 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL3000994 0.73 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL4059888 0.70 TSHR (0.54) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL10728205 0.69 PDE4D (0.44) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL10960291 0.69 MEN1 (0.50) ALDH1A1LMNAKDM4ERAB9AMEN1
SCHEMBL4257958 0.69 CACNA1C (0.46) ALDH1A1LMNAKDM4EMAPTGAA
SCHEMBL10960511 0.68 PDE4D (0.43) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL5962690 0.68 ADORA3 (0.53) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1
SCHEMBL2598061 0.68 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885LMNA 738/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885LMNA 738/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885LMNA 738/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885SMN1; SMN2 1739/4885LMNA 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.